Levetiracetam Rudipharm

Levetiracetam, the active ingredient in Levetiracetam Rudipharm, is an antiepileptic presented as a tablet for oral use. It is prescribed to manage various seizure types in adults and children with epilepsy.

GNH USA supplies Levetiracetam Rudipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets, and providing reliable logistics for timely delivery.

Levetiracetam is an antiepileptic drug used to control seizures across several epilepsy syndromes.

- Partial‑onset seizures: reduces the frequency of focal seizures in patients with epilepsy. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in both adults and children. - Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Somnolence: increased sleepiness or fatigue. - Irritability: mood changes such as agitation. - Headache: mild to moderate cranial pain. - Nausea: occasional stomach upset. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Mood disturbances: depression, suicidal thoughts, or aggressive behavior. - Hematologic abnormalities: thrombocytopenia or leukopenia. - Multi‑organ hypersensitivity: systemic rash with fever and organ involvement. - Severe skin reactions: bullous pemphigoid‑like eruptions. - Respiratory depression: when combined with other CNS depressants.

When prescribing Levetiracetam, clinicians should consider several safety measures and patient‑specific factors. - Renal impairment: adjust dose based on creatinine clearance. - History of psychiatric disorders: monitor mood and behavior closely. - Concomitant CNS depressants: observe for enhanced sedation. - Pregnancy: evaluate risk‑benefit; limited safety data are available. - Store at room temperature: keep in the original pack, protect from moisture.

Levetiracetam can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma concentrations. - Phenobarbital: can decrease exposure and seizure control. - Phenytoin: may lower levetiracetam levels. - Rifampin: induces metabolism, reducing effectiveness. - Other enzyme inducers: avoid co‑administration without monitoring.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression. - Sedative antihistamines: increased drowsiness. - Opioids: enhanced respiratory depression risk. - Valproate: monitor overall seizure control. - Hormonal contraceptives: may reduce efficacy, advise alternative methods.